Stockholders' Equity - Additional Information (Detail)									1 Months Ended		3 Months Ended		6 Months Ended			10 Months Ended	12 Months Ended			15 Months Ended
	Jun. 19, 2017 USD ($)	Jun. 14, 2017 $ / shares shares	Feb. 08, 2017 USD ($) shares	Aug. 24, 2016 USD ($) $ / shares shares	Jun. 20, 2016 shares	Apr. 29, 2016 USD ($) shares	Apr. 27, 2016 $ / shares shares	Apr. 13, 2016 USD ($) $ / shares shares	May 31, 2015 USD ($) $ / shares shares	Feb. 28, 2014 Tranche $ / shares shares	Jun. 30, 2017 USD ($) $ / shares shares	Mar. 31, 2017 USD ($) shares	Jun. 30, 2017 USD ($) $ / shares shares	Mar. 31, 2017 USD ($) shares	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) $ / shares shares	May 08, 2017	Feb. 20, 2014 USD ($)
Equity [Line Items]
Preferred stock, shares authorized											10,000,000		10,000,000			10,000,000	10,000,000	10,000,000		10,000,000
Preferred stock, par value | $ / shares											$ 0.00001		$ 0.00001			$ 0.00001	$ 0.00001	$ 0.00001		$ 0.00001
Preferred stock, shares outstanding											0		0			0	0	0		0
Common stock, shares authorized											300,000,000		300,000,000			300,000,000	300,000,000	300,000,000		300,000,000
Common stock, par value | $ / shares											$ 0.00001		$ 0.00001			$ 0.00001	$ 0.00001	$ 0.00001		$ 0.00001
Number of common stock for issuance in exchange for future services from founders										1,000,000
Common stock price per share | $ / shares										$ 0.01
Number of tranches | Tranche										2
Unrecognized compensation expense | $									$ 61,556													$ 168,000
Common stock shares repurchased									633,810
Repurchase of common stock from stockholders, per share | $ / shares									$ 0.00001
Remaining number of repurchased shares									366,190
Common stock sold						1,125,000		7,500,000
Warrants sold								7,500,000
Cash proceeds from common stock issuance | $						$ 1,283,400		$ 7,754,286					$ 6,582,278		$ 9,918,750
Common stock, price per share | $ / shares								$ 1.25
Warrants exercise price per share of common stock | $ / shares								$ 1.50			$ 10.00		$ 10.00			$ 10.00	$ 10.00
Number of additional common shares pursuant to over-allotment option granted to the underwriters								1,125,000
Underwriters grant period option								45 days
Additional warrants granted to underwriters								1,125,000
Additional warrants sold as a result of over allotment exercise								1,125,000
Public offering price per warrant | $ / shares								$ 0.01
Warrants expiry date								Apr. 13, 2021					Apr. 13, 2021
Underwriting discounts, commissions and other offering expenses | $						$ 111,600		$ 1,631,964
Repayments of notes payable in stock | $															$ 1,200,000
Over-allotment option exercised							1,125,000
Shares issued to cover future clinical study costs | $													$ 1,800,000
Securities Purchase Agreement [Member]
Equity [Line Items]
Public offering price per share and per warrant | $ / shares		$ 1.15
Over-Allotment Option [Member]
Equity [Line Items]
Warrants sold								1,125,000
Common stock, price per share | $ / shares							$ 1.24
Private Placement and Registered Direct Offering [Member] | Securities Purchase Agreement [Member]
Equity [Line Items]
Cash proceeds from common stock issuance | $	$ 3,900,000
Warrants exercise price per share of common stock | $ / shares		$ 1.30
Warrants expiry date		Dec. 19, 2022											Dec. 19, 2022
Number of warrants issued for common stock		0.75
Warrants exercisable date		Dec. 19, 2017											Dec. 19, 2017
Private Placement and Registered Direct Offering [Member] | Common Stock [Member] | Securities Purchase Agreement [Member]
Equity [Line Items]
Common stock sold		3,749,783
Minimum [Member] | Loan and Security Agreement [Member]
Equity [Line Items]
Beneficial ownership of company's common stock								49.90%													49.90%
Maximum [Member] | Private Placement and Registered Direct Offering [Member] | Common Stock [Member] | Securities Purchase Agreement [Member]
Equity [Line Items]
Warrants sold		2,812,337
Ligand [Member]
Equity [Line Items]
Common stock sold								560,000
Warrants sold								560,000
Ligand [Member] | Loan and Security Agreement [Member]
Equity [Line Items]
Common stock sold								960,000
Warrants sold								960,000
Warrants exercise price per share of common stock | $ / shares								$ 1.50
Warrants expiry date								Apr. 13, 2021					Apr. 13, 2021
Repayments of notes payable in stock | $								$ 1,200,000
Maxim [Member]
Equity [Line Items]
Cash proceeds from common stock issuance | $											$ 0	$ 0	$ 670,031	$ 670,031			$ 1,626,549
Maxim [Member] | Common Stock [Member]
Equity [Line Items]
Common stock sold											0	0	488,388	488,388			1,267,237
Maxim [Member] | Maximum [Member] | Common Stock [Member]
Equity [Line Items]
Sale of common stock, shares					3,748,726
Aspire Capital [Member] | Stock Purchase Agreement [Member]
Equity [Line Items]
Write off of remaining capitalized deferred financing costs | $	$ 336,985
Aspire Capital [Member] | Common Stock [Member] | Stock Purchase Agreement [Member]
Equity [Line Items]
Common stock sold				333,333							0		1,326,991			1,476,991
Cash proceeds from common stock issuance | $											$ 0		$ 1,869,512			$ 2,042,762
Common stock, price per share | $ / shares				$ 1.50
Common stock sold aggregate purchase price | $				$ 500,000
Common stock purchase agreement term				30 months
Minimum closing sale price per share to execute transactions under agreement | $ / shares				$ 0.40
Common stock issued as consideration for commitment fee				336,116
Shares issued to cover future clinical study costs | $												$ 440,278
Aspire Capital [Member] | Maximum [Member] | Common Stock [Member] | Stock Purchase Agreement [Member]
Equity [Line Items]
Common stock sold aggregate purchase price | $				$ 12,500,000
PoC Capital, LLC [Member]
Equity [Line Items]
Amortization expense | $											357,259		399,587
Prepaid clinical study costs | $			$ 1,800,000								1,400,413		1,400,413			$ 1,400,413	$ 1,400,413
PoC Capital, LLC [Member] | Common Stock [Member] | Stock Purchase Agreement [Member]
Equity [Line Items]
Common stock sold			1,286,173
PoC Capital, LLC [Member] | Common Stock [Member] | Stock Purchase Agreement [Member] | Clinical Studies [Member]
Equity [Line Items]
Common stock sold aggregate purchase price | $			$ 1,800,000
Tranche One [Member]
Equity [Line Items]
Number of common stock for issuance in exchange for future services from founders										500,000
Remaining number of repurchased shares									183,095
Stock compensation expense | $											$ 0		$ 0					$ 12,371	$ 18,407	$ 30,778
Tranche Two [Member]
Equity [Line Items]
Number of common stock for issuance in exchange for future services from founders										500,000
Remaining number of repurchased shares									183,095